GlassScriptPhysician profile
Gargi Gharat
NPI 1083252985
$636.72
in general payments reported to CMS, 2019-2025
14 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $473 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $169.41 | 2024-2025 | Ingrezza |
| Ucb, INC. | $114.14 | 2024 | Briviact, Zilbrysq |
| Neurelis, INC. | $58.47 | 2024 | Valtoco |
| Kyowa Kirin, INC. | $45.26 | 2024 | Nourianz |
| Lundbeck LLC | $35.99 | 2024 | Vyepti |
| Jazz Pharmaceuticals INC. | $33.95 | 2024 | |
| Argenx US, INC. | $28.85 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $26.26 | 2024 | Nuplazid |
| Tg Therapeutics, INC. | $24.91 | 2024 | |
| Csl Behring | $22.35 | 2024 | Hizentra |
| Springworks Therapeutics, INC. | $21.46 | 2024 | |
| Grifols USA, LLC | $21.27 | 2024 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $17.74 | 2025 | Ultomiris |
| Pfizer INC. | $16.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gargi Gharat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.